Evidence map›Paper›PMID 31194862›Full record

ArticleHuman molecular genetics2019

A mouse model of Proteus syndrome.

Marjorie J Lindhurst, Lauren R Brinster, Hannah C Kondolf, Jasmine J Shwetar, Miranda R Yourick, Henoke Shiferaw, Kim M Keppler-Noreuil, Gene Elliot, Cecilia Rivas, Lisa Garrett and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Human vascular organoids with a mosaicbioRxiv : the preprint server for biology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. PI3K inhibitors are finally coming of age.Nature reviews. Drug discovery · 2021
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Marjorie J LindhurstMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA.
Lauren R BrinsterDivision of Veterinary Resources, Office of Research Services, NIH, Bethesda, MD, USA.
Hannah C KondolfMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA.
Jasmine J ShwetarMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA.
Miranda R YourickMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA.
Henoke ShiferawMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA.
Kim M Keppler-NoreuilMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA.
Gene ElliotGenetic Disease Research Branch, NHGRI, NIH, Bethesda, MD, USA.
Cecilia RivasGenetic Disease Research Branch, NHGRI, NIH, Bethesda, MD, USA.
Lisa GarrettGenetic Disease Research Branch, NHGRI, NIH, Bethesda, MD, USA.
Julio Gomez-RodriguezGenetic Disease Research Branch, NHGRI, NIH, Bethesda, MD, USA.
Neil J SebireHistopathology Department, Great Ormond Street Hospital NIHR Biomedical Research Centre, London, UK.
Stephen M HewittLaboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD, USA.
Pamela L SchwartzbergGenetic Disease Research Branch, NHGRI, NIH, Bethesda, MD, USA.
Leslie G BieseckerMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA.
National Human Genome Research Institute · USGreat Ormond Street Hospital · GBNational Cancer Institute · USOffice of Research Services · US

Funding

Rare & Mosaic Disorders Molecular ResearchZIAHG200328 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BIESECKER, LESLIE · 2009 to 2025
$26.8M
NHGRI/DIR Embryonic Stem Cell and Transgenic Mouse CoreZICHG200349 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BURGESS, SHAWN M · 2010 to 2025
$23.8M
Genetic and Biochemical Approaches to Tyrosine Kinase and Lymphocyte SignalingZIAAI001240 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SCHWARTZBERG, PAMELA · 2019 to 2025
$18.8M
Clinical and Molecular Studies of MalformationsZ01HG200328 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BIESECKER, LESLIE G · 2005 to 2008
$5.5M
Intramural NIH HHS Z01 HG200328
6 · The paper itself

Abstract

Proteus syndrome is a mosaic, progressive overgrowth disorder caused by a somatic activating variant c.49G > A p.(E17K) in AKT1. The presentation in affected individuals is variable, with a diversity of tissues demonstrating abnormalities. Common manifestations include skin and bony overgrowth, vascular malformations (VMs), cysts and benign tumors. We used two methods to create mouse models that had endogenously-regulated mosaic expression of the Proteus syndrome variant. Variant allele fractions (VAFs) ranged from 0% to 50% across numerous tissues in 44 Proteus syndrome mice. Mice were phenotypically heterogeneous with lesions rarely observed before 12 months of age. VMs were the most frequent finding with a total of 69 found in 29 of 44 Proteus syndrome mice. Twenty-eight cysts and ectasia, frequently biliary, were seen in 22 of 44 Proteus syndrome mice. Varying levels of mammary hyperplasia were seen in 10 of 16 female Proteus syndrome mice with other localized regions of hyperplasia and stromal expansion noted in several additional animals. Interestingly, 27 of 31 Proteus syndrome animals had non-zero blood VAF that is in contrast to the human disorder where it is rarely seen in peripheral blood. Identification of variant-positive cells by green fluorescent protein (GFP) staining in chimeric Proteus syndrome mice showed that in some lesions, hyperplastic cells were predominantly GFP/Akt1E17K-positive and showed increased pAKT signal compared to GFP-negative cells. However, hyperplastic mammary epithelium was a mixture of GFP/Akt1E17K-positive and negative cells with some GFP/Akt1E17K-negative cells also having increased pAKT signal suggesting that the variant-positive cells can induce lesion formation in a non-cell autonomous manner.

Indexed as

Disease Models, AnimalGenetic Association StudiesGenetic Predisposition to DiseaseMutationPhenotypeAllelesAnimalsBiopsyGenetic LociGenotypeHumansMiceProteus SyndromeProto-Oncogene Proteins c-aktAkt1 protein, mouseProto-Oncogene Proteins c-akt

Identifiers

PMID31194862
PMCPMC6736390
OpenAlexW2950416686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.